RxDoctor Payments Data

Michael Chiles

Psychiatric/Mental Health · Mount Pleasant, TXNPI 1720846066

Payments from drug & device makers

$1,589in general payments, 2019–2025

Across 88 payments — averaging $18.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vanda Pharmaceuticals Inc.$410
  • Teva Pharmaceuticals USA, Inc.$336
  • AbbVie$242
  • E.r. Squibb & Sons, L.L.C.$178
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$126
  • Alkermes, Inc.$73
  • plus $223 from 6 others

What the payments were for

  • Food & beverage$1,47793%
  • Education$1117%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,589 in reported general payments places this provider in the 70th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$4,266
Medicare patients
21
Services billed
48

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl112$169,466
IngrezzaValbenazine Tosylate14$116,829
Invega SustennaPaliperidone Palmitate27$83,546
Abilify MaintenaAripiprazole14$42,029
CaplytaLumateperone Tosylate14$24,709
LybalviOlanzapine/Samidorphan Malate12$20,008
TrintellixVortioxetine Hydrobromide20$10,157
Aripiprazole78$3,726
Lurasidone Hcl23$2,576
Duloxetine Hcl72$2,418
Buspirone Hcl197$2,257
Quetiapine Fumarate160$1,859
Hydroxyzine Pamoate100$1,566
Hydroxyzine Hcl49$1,513
Doxepin Hcl37$1,349

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$242$169,466112 claims
Neurocrine Biosciences, Inc.Ingrezza$61$116,82914 claims
Johnson & JohnsonInvega Sustenna$25$83,54627 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$41$42,02914 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$126$24,70914 claims
Alkermes, Inc.Lybalvi$73$20,00812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in Mount Pleasant

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →